search
Back to results

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Primary Purpose

Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Zimberelimab (ZIM)
Domvanalimab (DOM)
Sacituzumab govitecan-hziy (SG)
Etrumadenant (ETRUMA)
Carboplatin
Cisplatin
Pemetrexed
Paclitaxel
Nab-paclitaxel
Docetaxel
Nivolumab
Sponsored by
Gilead Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: All Substudies: Histologically or cytologically documented non-small-cell lung cancer (NSCLC). No known actionable genomic alterations for which targeted therapies are available. Eastern cooperative oncology group (ECOG) performance status score of 0 or 1. Measurable disease per response evaluation criteria in solid tumors. Adequate hematologic and end-organ function. Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception. Substudy 01: All Experimental arms Stage IV NSCLC. For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. PD-L1 status by central confirmation. No prior systemic treatment for metastatic NSCLC. Substudy 02: All Experimental arms Stage IV NSCLC. In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration. Substudy 03: All Experimental arms Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8). Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy. PD-L1 status by central confirmation. For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. Key Exclusion Criteria: All Substudies: Mixed small-cell lung cancer and NSCLC histology. Active second malignancy. Active autoimmune disease. History of or current non-infectious pneumonitis/interstitial lung disease. Active serious infection within 4 weeks prior to study treatment. Substudy 01 and 02 Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Received previous anticancer therapy within 4 weeks prior to enrollment. Substudy 03: All Experimental arms NSCLC previously treated with systemic therapy or radiotherapy. Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs). Note: Other protocol defined inclusion/exclusion criteria may apply

Sites / Locations

  • Arizona Oncology Associates,Substudy-01Recruiting
  • Arizona Oncology Associates,Substudy-02Recruiting
  • Rocky Mountain Cancer Center,Substudy-01Recruiting
  • Rocky Mountain Cancer Center,Substudy-02Recruiting
  • Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03Recruiting
  • Washington University School of Medicine - Siteman Cancer Center,Substudy-01Recruiting
  • Washington University School of Medicine - Siteman Cancer Center,Substudy-02
  • Washington University School of Medicine - Siteman Cancer CenterRecruiting
  • Oncology Hematology Care Clinical Trials, LLC,Substudy-01Recruiting
  • Oncology Hematology Care Clinical Trials, LLC,Substudy-02Recruiting
  • Oncology Associates of Oregon, PC,Substudy-01Recruiting
  • Oncology Associates of Oregon, PC,Substudy-02Recruiting
  • Texas Oncology,Substudy-01Recruiting
  • Texas Oncology,Substudy-02Recruiting
  • US Oncology Investigational Products Center (IPC),Substudy-01Recruiting
  • US Oncology Investigational Products Center (IPC),Substudy-02Recruiting
  • Fred Hutchinson Cancer Center,Substudy-01Recruiting
  • Fred Hutchinson Cancer Center,Substudy-02Recruiting
  • Queen Mary Hospital,Substudy-01Recruiting
  • Queen Mary Hospital,Substudy-02Recruiting
  • Prince of Wales Hospital,Substudy-02Recruiting
  • Rambam Health Care Campus,Substudy-01Recruiting
  • Rambam Health Care Campus,Substudy-02
  • Shaare Zedek Medical Center,Substudy-01Recruiting
  • Shaare Zedek Medical Center,Substudy-02
  • Tel Aviv Sourasky Medical Center,Substudy-01Recruiting
  • Tel Aviv Sourasky Medical Center,Substudy-02
  • Chungbuk National University Hospital,Substudy-01Recruiting
  • Chungbuk National University Hospital,Substudy-02Recruiting
  • National Cancer Center,Substudy-01Recruiting
  • National Cancer Center,Substudy-02
  • Asan Medical Center,Substudy-02
  • Asan Medical Centre,Substudy-01Recruiting
  • Samsung Medical Center,Substudy-01Recruiting
  • Samsung Medical Center,Substudy-02
  • Severance Hospital, Yonsei University Health System,Substudy-01Recruiting
  • Severance Hospital, Yonsei University Health System,Substudy-02
  • Seoul National University,Substudy-01Recruiting
  • Seoul National University,Substudy-02Recruiting
  • Changhua Christian Hospital,Substudy-01Recruiting
  • Changhua Christian Hospital,Substudy-02
  • Kaohsiung Chang Gung Memorial Hospital,Substudy-01Recruiting
  • Kaohsiung Chang Gung Memorial Hospital,Substudy-02
  • National Taiwan University Hospital,Substudy-01Recruiting
  • National Taiwan University Hospital,Substudy-02

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Experimental

Active Comparator

Experimental

Experimental

Active Comparator

Arm Label

Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)

Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)

Substudy 01: ZIM + ETRUMA

Substudy 01: ZIM + Platinum Based Chemotherapy

Substudy 02: SG + ZIM + ETRUMA

Substudy 02: Either Docetaxel or SG (Monotherapy Only)

Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy

Substudy 03 - ZIM + Platinum-based Chemotherapy

Substudy 03: Nivolumab + Platinum-based Chemotherapy

Arm Description

Participants will receive ZIM, SG and DOM until disease progression (PD)/disease recurrence or unacceptable toxicity.

Participants will receive ZIM, DOM and ETRUMA until PD/disease recurrence or unacceptable toxicity.

Participants will receive ZIM and ETRUMA until PD/disease recurrence or unacceptable toxicity.

Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be cisplatin or carboplatin and pemetrexed (non-squamous histology) or carboplatin, paclitaxel and nabpaclitaxel (squamous histology).

Participants will receive SG, ZIM and ETRUMA until PD/disease recurrence or unacceptable toxicity.

Participants will receive either Docetaxel or SG until PD/disease recurrence or unacceptable toxicity.

Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).

Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).

Participants will receive nivolumab plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).

Outcomes

Primary Outcome Measures

Substudies 1 and 2: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
ORR is defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as confirmed at least 4 weeks after the first detection of response.
Substudy 3: Complete Pathological Response (pCR) Rate
pCR is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes as assessed by local pathology review.

Secondary Outcome Measures

Substudies 1 and 2: Progression-free Survival (PFS) According to RECIST Version 1.1
PFS is defined as the time from the date of randomization until disease progression (PD) or death, whichever comes first.
Substudies 1 and 2: Duration of response (DOR) According to RECIST Version 1.1
DOR is defined as the time from the first response (CR or PR) until the first documented PD, or death, whichever comes first.
All Substudies: Overall survival (OS)
OS is defined as the time from the date of randomization until death from any cause.
Substudy 3: Event-Free Survival (EFS)
Event-Free Survival (EFS) is defined as the time from randomization until any of the following events: any progression precluding surgery or preventing completion of surgery, progression or recurrence of disease after surgery (local or distant), as assessed by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), or death due to any cause, whichever occurs first. Participants who do not undergo surgery for reasons other than progression will be considered to have had an event at progression or at death.
Substudy 3: Major Pathological Response (MPR) Rate
MPR rate is defined as the percentage of participants with ≤ 10% residual tumor in lung and lymph nodes at surgery as evaluated by local pathology review.
All Substudies: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Related TEAEs
All Substudies: Percentage of Participants Experiencing Clinical Laboratory Abnormalities

Full Information

First Posted
November 21, 2022
Last Updated
October 12, 2023
Sponsor
Gilead Sciences
Collaborators
Arcus Biosciences, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05633667
Brief Title
Study of Novel Treatment Combinations in Patients With Lung Cancer
Acronym
VELOCITY-Lung
Official Title
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 16, 2023 (Actual)
Primary Completion Date
January 2027 (Anticipated)
Study Completion Date
January 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gilead Sciences
Collaborators
Arcus Biosciences, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
397 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)
Arm Type
Experimental
Arm Description
Participants will receive ZIM, SG and DOM until disease progression (PD)/disease recurrence or unacceptable toxicity.
Arm Title
Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)
Arm Type
Experimental
Arm Description
Participants will receive ZIM, DOM and ETRUMA until PD/disease recurrence or unacceptable toxicity.
Arm Title
Substudy 01: ZIM + ETRUMA
Arm Type
Experimental
Arm Description
Participants will receive ZIM and ETRUMA until PD/disease recurrence or unacceptable toxicity.
Arm Title
Substudy 01: ZIM + Platinum Based Chemotherapy
Arm Type
Active Comparator
Arm Description
Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be cisplatin or carboplatin and pemetrexed (non-squamous histology) or carboplatin, paclitaxel and nabpaclitaxel (squamous histology).
Arm Title
Substudy 02: SG + ZIM + ETRUMA
Arm Type
Experimental
Arm Description
Participants will receive SG, ZIM and ETRUMA until PD/disease recurrence or unacceptable toxicity.
Arm Title
Substudy 02: Either Docetaxel or SG (Monotherapy Only)
Arm Type
Active Comparator
Arm Description
Participants will receive either Docetaxel or SG until PD/disease recurrence or unacceptable toxicity.
Arm Title
Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy
Arm Type
Experimental
Arm Description
Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).
Arm Title
Substudy 03 - ZIM + Platinum-based Chemotherapy
Arm Type
Experimental
Arm Description
Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).
Arm Title
Substudy 03: Nivolumab + Platinum-based Chemotherapy
Arm Type
Active Comparator
Arm Description
Participants will receive nivolumab plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).
Intervention Type
Drug
Intervention Name(s)
Zimberelimab (ZIM)
Other Intervention Name(s)
AB122, GS-0122
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Domvanalimab (DOM)
Other Intervention Name(s)
AB154, GS-0154
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Sacituzumab govitecan-hziy (SG)
Other Intervention Name(s)
GS-0132, IMMU-132
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Etrumadenant (ETRUMA)
Other Intervention Name(s)
AB928, GS-0928
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Pemetrexed
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Nab-paclitaxel
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Docetaxel
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Intervention Description
Administered intravenously
Primary Outcome Measure Information:
Title
Substudies 1 and 2: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Description
ORR is defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as confirmed at least 4 weeks after the first detection of response.
Time Frame
Up to 5 years
Title
Substudy 3: Complete Pathological Response (pCR) Rate
Description
pCR is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes as assessed by local pathology review.
Time Frame
Up to 5 years
Secondary Outcome Measure Information:
Title
Substudies 1 and 2: Progression-free Survival (PFS) According to RECIST Version 1.1
Description
PFS is defined as the time from the date of randomization until disease progression (PD) or death, whichever comes first.
Time Frame
Up to 5 years
Title
Substudies 1 and 2: Duration of response (DOR) According to RECIST Version 1.1
Description
DOR is defined as the time from the first response (CR or PR) until the first documented PD, or death, whichever comes first.
Time Frame
Up to 5 years
Title
All Substudies: Overall survival (OS)
Description
OS is defined as the time from the date of randomization until death from any cause.
Time Frame
Up to 5 years
Title
Substudy 3: Event-Free Survival (EFS)
Description
Event-Free Survival (EFS) is defined as the time from randomization until any of the following events: any progression precluding surgery or preventing completion of surgery, progression or recurrence of disease after surgery (local or distant), as assessed by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), or death due to any cause, whichever occurs first. Participants who do not undergo surgery for reasons other than progression will be considered to have had an event at progression or at death.
Time Frame
Up to 5 years
Title
Substudy 3: Major Pathological Response (MPR) Rate
Description
MPR rate is defined as the percentage of participants with ≤ 10% residual tumor in lung and lymph nodes at surgery as evaluated by local pathology review.
Time Frame
Up to 5 years
Title
All Substudies: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Related TEAEs
Time Frame
First dose date up to 24 months plus 100 days
Title
All Substudies: Percentage of Participants Experiencing Clinical Laboratory Abnormalities
Time Frame
First dose date up to 24 months plus 100 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: All Substudies: Histologically or cytologically documented non-small-cell lung cancer (NSCLC). No known actionable genomic alterations for which targeted therapies are available. Eastern cooperative oncology group (ECOG) performance status score of 0 or 1. Measurable disease per response evaluation criteria in solid tumors. Adequate hematologic and end-organ function. Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception. Substudy 01: All Experimental arms Stage IV NSCLC. For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. PD-L1 status by central confirmation. No prior systemic treatment for metastatic NSCLC. Substudy 02: All Experimental arms Stage IV NSCLC. In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration. Substudy 03: All Experimental arms Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8). Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy. PD-L1 status by central confirmation. For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative. Key Exclusion Criteria: All Substudies: Mixed small-cell lung cancer and NSCLC histology. Active second malignancy. Active autoimmune disease. History of or current non-infectious pneumonitis/interstitial lung disease. Active serious infection within 4 weeks prior to study treatment. Substudy 01 and 02 Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Received previous anticancer therapy within 4 weeks prior to enrollment. Substudy 03: All Experimental arms NSCLC previously treated with systemic therapy or radiotherapy. Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs). Note: Other protocol defined inclusion/exclusion criteria may apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gilead Clinical Study Information Center
Phone
1-833-445-3230 (GILEAD-0)
Email
GileadClinicalTrials@gilead.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilead Study Director
Organizational Affiliation
Gilead Sciences
Official's Role
Study Director
Facility Information:
Facility Name
Arizona Oncology Associates,Substudy-01
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85711
Country
United States
Individual Site Status
Recruiting
Facility Name
Arizona Oncology Associates,Substudy-02
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85711
Country
United States
Individual Site Status
Recruiting
Facility Name
Rocky Mountain Cancer Center,Substudy-01
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Name
Rocky Mountain Cancer Center,Substudy-02
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Name
Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46845
Country
United States
Individual Site Status
Recruiting
Facility Name
Washington University School of Medicine - Siteman Cancer Center,Substudy-01
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Name
Washington University School of Medicine - Siteman Cancer Center,Substudy-02
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Washington University School of Medicine - Siteman Cancer Center
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Name
Oncology Hematology Care Clinical Trials, LLC,Substudy-01
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Individual Site Status
Recruiting
Facility Name
Oncology Hematology Care Clinical Trials, LLC,Substudy-02
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Individual Site Status
Recruiting
Facility Name
Oncology Associates of Oregon, PC,Substudy-01
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Individual Site Status
Recruiting
Facility Name
Oncology Associates of Oregon, PC,Substudy-02
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology,Substudy-01
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology,Substudy-02
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
Individual Site Status
Recruiting
Facility Name
US Oncology Investigational Products Center (IPC),Substudy-01
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Name
US Oncology Investigational Products Center (IPC),Substudy-02
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Name
Fred Hutchinson Cancer Center,Substudy-01
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Name
Fred Hutchinson Cancer Center,Substudy-02
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Name
Queen Mary Hospital,Substudy-01
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Queen Mary Hospital,Substudy-02
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Prince of Wales Hospital,Substudy-02
City
New Territories
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Rambam Health Care Campus,Substudy-01
City
Haifa
ZIP/Postal Code
3525408
Country
Israel
Individual Site Status
Recruiting
Facility Name
Rambam Health Care Campus,Substudy-02
City
Haifa
ZIP/Postal Code
3525408
Country
Israel
Individual Site Status
Active, not recruiting
Facility Name
Shaare Zedek Medical Center,Substudy-01
City
Jerusalem
ZIP/Postal Code
9103102
Country
Israel
Individual Site Status
Recruiting
Facility Name
Shaare Zedek Medical Center,Substudy-02
City
Jerusalem
ZIP/Postal Code
9103102
Country
Israel
Individual Site Status
Active, not recruiting
Facility Name
Tel Aviv Sourasky Medical Center,Substudy-01
City
Tel Aviv-Yafo
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Recruiting
Facility Name
Tel Aviv Sourasky Medical Center,Substudy-02
City
Tel Aviv-Yafo
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Active, not recruiting
Facility Name
Chungbuk National University Hospital,Substudy-01
City
Cheongju-si
ZIP/Postal Code
28644
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Chungbuk National University Hospital,Substudy-02
City
Cheongju-si
ZIP/Postal Code
28644
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
National Cancer Center,Substudy-01
City
Goyang
ZIP/Postal Code
410769
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
National Cancer Center,Substudy-02
City
Goyang
ZIP/Postal Code
410769
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Asan Medical Center,Substudy-02
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Asan Medical Centre,Substudy-01
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Samsung Medical Center,Substudy-01
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Samsung Medical Center,Substudy-02
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Severance Hospital, Yonsei University Health System,Substudy-01
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Severance Hospital, Yonsei University Health System,Substudy-02
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University,Substudy-01
City
Seoul
ZIP/Postal Code
463-707
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Seoul National University,Substudy-02
City
Seoul
ZIP/Postal Code
463-707
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Changhua Christian Hospital,Substudy-01
City
Changhua City
ZIP/Postal Code
500-06
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Changhua Christian Hospital,Substudy-02
City
Changhua City
ZIP/Postal Code
500-06
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Kaohsiung Chang Gung Memorial Hospital,Substudy-01
City
Kaohsiung
ZIP/Postal Code
83301
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Kaohsiung Chang Gung Memorial Hospital,Substudy-02
City
Kaohsiung
ZIP/Postal Code
83301
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
National Taiwan University Hospital,Substudy-01
City
Taipei City
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
National Taiwan University Hospital,Substudy-02
City
Taipei City
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.gileadclinicaltrials.com/study/?id=GS-US-624-6376
Description
Gilead Clinical Trials Website

Learn more about this trial

Study of Novel Treatment Combinations in Patients With Lung Cancer

We'll reach out to this number within 24 hrs